ArticleOncoimmunology2021

Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance.

Hanna Grauers Wiktorin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.